Greater Per-Read Accuracy
PacBio Vega™ HiFi sequencing delivers greater than 99.9% per-read accuracy, helping reduce uncertainty and support more confident clinical interpretation.
The sequencing platform a laboratory chooses is not a back-office equipment decision. It determines the accuracy of every result that leaves the lab. US-Biosciences runs on the PacBio Vega™ HiFi long-read sequencing system, a platform built to deliver exceptional accuracy and resolve complex gene regions that conventional short-read platforms routinely cannot.
Providers rely on laboratory results to guide real clinical decisions. That means the technology behind those results must do more than process samples. It must deliver clarity, completeness, and confidence.
PacBio Vega™ HiFi sequencing delivers greater than 99.9% per-read accuracy, helping reduce uncertainty and support more confident clinical interpretation.
Long-read sequencing can span complex genomic regions that short-read platforms may struggle to resolve, giving providers a more complete view of clinically relevant variation.
HiFi sequencing combines long-read visibility with high accuracy, allowing US-Biosciences to identify variants with the precision modern molecular diagnostics demand.
Better technology is not just a laboratory advantage. It changes what providers can see, interpret, and act on for their patients.
Higher sequencing accuracy helps reduce ambiguous findings and supports cleaner, more actionable reporting for clinical teams.
Medication response can be influenced by complex genetic variation. HiFi long-read sequencing helps provide a more complete view of relevant pharmacogenomic markers.
Some hereditary cancer risk regions are difficult to evaluate with limited sequencing approaches. PacBio Vega™ helps US-Biosciences pursue a deeper, clearer genetic picture.
Repeat expansion disorders can be missed by conventional testing methods. Long-read sequencing provides the visibility needed to identify these challenging genomic patterns.
We did not choose PacBio Vega™ because it was available. We chose it because our providers and their patients deserve the most accurate results the industry can produce.
The human genome contains regions that are difficult to read, map, and interpret. Our technology choice reflects that reality.
Providers need results they can trust. Every sequencing decision we make is tied to improving clarity at the point of care.
Accurate testing supports better decisions, better patient conversations, and better paths forward when answers matter most.
Connect with US-Biosciences to learn how PacBio Vega™ HiFi long-read sequencing supports more complete, more confident clinical testing.